Patents Assigned to MTI Meta Tech Inc.
  • Patent number: 8536140
    Abstract: A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: September 17, 2013
    Assignee: MTI Meta Tech Inc.
    Inventors: Michael Thomas Clandinin, Eek J. Park
  • Publication number: 20110144041
    Abstract: A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.
    Type: Application
    Filed: December 13, 2010
    Publication date: June 16, 2011
    Applicant: MTI META TECH INC.
    Inventors: Michael Thomas Clandinin, Eek J. Park
  • Patent number: 7851451
    Abstract: The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: December 14, 2010
    Assignee: MTI Meta Tech Inc.
    Inventors: Michael Thomas Clandinin, Eek Joong Park
  • Patent number: 7781408
    Abstract: The invention provides formulations for mediating inflammation and for lowering blood cholesterol. For example, inflammation of the intestine, retina or neural tissues, may be mediated. Further the formulations are effective in decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, GD1b, NANA, and sialic acid. The invention further provides a method of treating or preventing inflammatory diseases by delivery of at least one ganglioside to a subject in need thereof, and a method of reducing blood cholesterol in a subject be delivery of a ganglioside-containing formulation. The formulation of the invention may be used to supplement foods or liquids, and may for example be used in preparation of infant formula or foods.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: August 24, 2010
    Assignee: MTI Meta Tech Inc.
    Inventors: Michael Thomas Clandinin, Eek J. Park
  • Publication number: 20070173480
    Abstract: The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.
    Type: Application
    Filed: January 12, 2007
    Publication date: July 26, 2007
    Applicant: MTI META TECH INC.
    Inventors: Michael CLANDININ, Eek PARK
  • Patent number: 6998392
    Abstract: The invention provides a formulation for treatment or prevention of a parasitic infection such as a protozoan or helminths infection, for example: Giardia. The formulation comprises at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, GD1b, NANA, and sialic acid. The formulation may be used to supplement foods or liquids, for example: infant formula, baby food, baby cereal, juice, dehydrated camping food, or bottled water.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: February 14, 2006
    Assignee: MTI Meta Tech Inc.
    Inventors: Michael Thomas Clandinin, Miyoung Suh, Miodrag Belosevic